Imatinib Mesylate ( DrugBank: Imatinib )

5 diseases

告示番号	疾患名（ページ内リンク）	臨床試験数
13	多発性硬化症／視神経脊髄炎	1
28	全身性アミロイドーシス	1
34	神経線維腫症	4
51	全身性強皮症	7
86	肺動脈性肺高血圧症	16

13. 多発性硬化症／視神経脊髄炎

臨床試験数 : 3,340 / 薬物数 : 2,163 - (DrugBank : 383) / 標的遺伝子数 : 241 - 標的パスウェイ数 : 238

diseases per page:

Showing 1 to 1 of 1 diseases

Filter by

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT03674099 (ClinicalTrials.gov)	October 1, 2018	14/9/2018	Imatinib for Multiple Sclerosis (MS) Relapses	Imatinib for Multiple Sclerosis (MS) Relapses - a Phase II, Randomised Study	Multiple Sclerosis	Drug: Imatinib Mesylate;Drug: Methylprednisolone	Tomas Olsson	The Swedish Research Council	Recruiting	18 Years	55 Years	All	200	Phase 2	Denmark;Germany;Norway;Sweden

First Previous1Next Last

28. 全身性アミロイドーシス

臨床試験数 : 267 / 薬物数 : 241 - (DrugBank : 77) / 標的遺伝子数 : 68 - 標的パスウェイ数 : 180

diseases per page:

Showing 1 to 1 of 1 diseases

Filter by

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT00025415 (ClinicalTrials.gov)	August 2001	11/10/2001	Imatinib Mesylate in Treating Patients With Advanced Cancer and Liver Dysfunction	A Phase I Pharmacokinetic Study of STI571 in Patients With Advanced Malignancies and Varying Levels ...	Accelerated Phase Chronic Myelogenous Leukemia;Acute Undifferentiated Leukemia;AIDS-related Peripher ...	Drug: imatinib mesylate;Other: pharmacological study	National Cancer Institute (NCI)	NULL	Completed	15 Years	N/A	Both	60	Phase 1	United States

First Previous1Next Last

34. 神経線維腫症

臨床試験数 : 133 / 薬物数 : 186 - (DrugBank : 67) / 標的遺伝子数 : 79 - 標的パスウェイ数 : 190

diseases per page:

Showing 1 to 4 of 4 diseases

Filter by

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT03688568 (ClinicalTrials.gov)	September 1, 2018	11/9/2018	Study of Imatinib in Children With Neurofibromatosis and Airway Tumors	Phase 2 Study of Imatinib in Children With Neurofibromatosis and Airway Tumors	Neurofibroma, Plexiform	Drug: Imatinib Mesylate	Indiana University	NULL	Withdrawn	6 Months	12 Years	All	0	Phase 2	United States
2	NCT02177825 (ClinicalTrials.gov)	June 2014	25/6/2014	Study of Imatinib Mesylatein Neurofibromatosis Type I Patients Aged 2 to 21 With Plexiform Neurofibr ...	Phase II Study of Imatinib Mesylatein Neurofibromatosis Type I Patients Aged 2 to 21 With Plexiform ...	Plexiform Neurofibromas	Drug: Imatinib Mesylate	St. Justine's Hospital	NULL	Terminated	2 Years	21 Years	All	5	Phase 2	Canada
3	NCT01140360 (ClinicalTrials.gov)	February 2012	8/6/2010	Pilot Study of Gleevec/Imatinib Mesylate(STI-571, NSC 716051) in Neurofibromatosis (NF1) Patient Wit ...	Pilot Study of Gleevec/Imatinib Mesylate(STI-571, NSC 716051) in Neurofibromatosis (NF1) Patient Wit ...	Neurofibromatosis;Neurofibromas	Drug: Gleevec	Kent Robertson	NULL	Completed	3 Years	65 Years	All	21	Phase 1/Phase 2	United States
4	NCT01673009 (ClinicalTrials.gov)	May 2006	22/8/2012	Phase II Study of Gleevec/Imatinib Mesylate(STI-571, NCS 716051) in Neurofibromatosis (NF1) Patients ...	Phase II Study of Gleevec/Imatinib Mesylate(STI-571, NCS 716051) in Neurofibromatosis (NF1) Patients ...	Neurofibromatosis	Drug: Gleevec	Indiana University	NULL	Completed	3 Years	65 Years	All	36	Phase 2	United States

First Previous1Next Last

51. 全身性強皮症

臨床試験数 : 525 / 薬物数 : 565 - (DrugBank : 148) / 標的遺伝子数 : 114 - 標的パスウェイ数 : 217

diseases per page:

Showing 1 to 7 of 7 diseases

Filter by

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT01309997 (ClinicalTrials.gov)	March 2011	1/3/2011	Imatinib and Rituximab in Treating Cutaneous Sclerosis in Patients With Chronic Graft-Versus-Host Di ...	A Randomized Phase II Study of Imatinib and Rituximab for Cutaneous Sclerosis After Allogeneic Hemat ...	Graft Versus Host Disease;Systemic Scleroderma	Drug: imatinib mesylate;Biological: rituximab	Lee, Stephanie	National Cancer Institute (NCI)	Completed	2 Years	N/A	All	72	Phase 2	United States
2	NCT01545427 (ClinicalTrials.gov)	April 2008	1/3/2012	Proof of Concept Trial of Gleevec (Imatinib) in Active Diffuse Scleroderma	A Proof of Concept Trial of Gleevec (Imatinib) in Active Diffuse Scleroderma	Scleroderma	Drug: Imatinib mesylate;Other: Placebo	Lawson Health Research Institute	Novartis Pharmaceuticals	Terminated	18 Years	N/A	Both	10	Phase 2	Canada
3	NCT00613171 (ClinicalTrials.gov)	January 2, 2008	25/1/2008	Efficacy and Tolerability of STI571 (Imatinib Mesylate) for the Treatment of Fibrosis in Participant ...	A Multi-centre, Open-label, Proof of Concept (PoC) Study to Evaluate the Efficacy and Tolerability o ...	Systemic Sclerosis, Scleroderma	Drug: STI571	Novartis Pharmaceuticals	NULL	Completed	18 Years	N/A	All	27	Phase 2	United States;Germany;Italy;Switzerland;United Kingdom
4	NCT00479934 (ClinicalTrials.gov)	December 2007	29/5/2007	Efficacy and Safety of Imatinib in Scleroderma	Phase II Randomized Double Blind Clinical Trial of'Imatinib MesylateSTI571 (Glivec®) Versus Placebo ...	Scleroderma, Localized;Scleroderma, Systemic	Drug: imatinib mesylate	University Hospital, Bordeaux	Ministry of Health, France;Novartis	Completed	18 Years	N/A	Both	28	Phase 2	France
5	EUCTR2006-007091-15-NL (EUCTR)	03/09/2007	02/04/2007	Glivec (imatinib mesylate) in systemic sclerosis, a pilot study - Glivec in systemic sclerosis	Glivec (imatinib mesylate) in systemic sclerosis, a pilot study - Glivec in systemic sclerosis	systemic sclerosis MedDRA version: 9.1;Level: LLT;Classification code 10039710;Term: Scleroderma	Product Name: Glivec	ErasmusMC	NULL	Authorised-recruitment may be ongoing or finished			Female: yes Male: yes	10		Netherlands
6	NCT00555581 (ClinicalTrials.gov)	August 2007	7/11/2007	Imatinib Mesylate (Gleevec) in the Treatment of Systemic Sclerosis	Phase IIA Study of the Safety and Tolerability of the Use of Imatinib Mesylate(Gleevec) in the Treat ...	Systemic Sclerosis	Drug: Imatinib Mesylate	Hospital for Special Surgery, New York	Novartis Pharmaceuticals	Completed	18 Years	N/A	All	30	Phase 2	United States
7	NCT00506831 (ClinicalTrials.gov)	July 2007	24/7/2007	Imatinib in Systemic Sclerosis	A Pilot Study of Imatinib in the Treatment of Refractory Systemic Sclerosis	Scleroderma, Systemic	Drug: Imatinib mesylate	Stanford University	NULL	Completed	18 Years	80 Years	All	9	Phase 1/Phase 2	United States

First Previous1Next Last

先頭へ

86. 肺動脈性肺高血圧症

臨床試験数 : 1,205 / 薬物数 : 684 - (DrugBank : 124) / 標的遺伝子数 : 100 - 標的パスウェイ数 : 193

diseases per page:

Showing 1 to 10 of 16 diseases

Filter by

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT04416750 (ClinicalTrials.gov)	January 20, 2021	28/5/2020	Positioning Imatinib for Pulmonary Arterial Hypertension	Positioning Imatinib for Pulmonary Arterial Hypertension	Pulmonary Arterial Hypertension	Drug: Imatinib Mesylate	Imperial College London	National Institute for Health Research, United Kingdom;Medical Research Council;University of Cambri ...	Recruiting	18 Years	80 Years	All	43	Phase 2	United Kingdom
2	EUCTR2010-021960-14-IT (EUCTR)	11/03/2011	26/05/2011	An open-label extension study to CQTI571A2102 to evaluate the long-term safety, tolerability and eff ...	An open-label extension study to CQTI571A2102 to evaluate the long-term safety, tolerability and eff ...	Pulmonary arterial hypertension (PAH) MedDRA version: 13.1;Level: PT;Classification code 10064911;Te ...	Trade Name: GLIVEC INN or Proposed INN: IMATINIB MESYLATE	NOVARTIS FARMA	NULL	Not Recruiting			Female: yes Male: yes	20		Germany;Italy
3	EUCTR2010-021344-17-IT (EUCTR)	28/01/2011	07/02/2011	A non-randomized, multiple dose, three treatment period, open-label, single sequence, single group s ...	A non-randomized, multiple dose, three treatment period, open-label, single sequence, single group s ...	Pulmonary arterial hypertension (PAH) MedDRA version: 9.1;Level: LLT;Classification code 10064911	Trade Name: GLIVEC INN or Proposed INN: IMATINIB MESYLATE Trade Name: REVATIO INN or Proposed INN: Sild ...	NOVARTIS FARMA	NULL	Not Recruiting			Female: yes Male: yes	24		Italy
4	EUCTR2009-018167-26-FR (EUCTR)	04/11/2010	13/09/2010	An extension study to QTI571A2301 to evaluate the longterm safety, tolerability and efficacy of oral ...	An extension study to QTI571A2301 to evaluate the longterm safety, tolerability and efficacy of oral ...	Pulmonary arterial hypertension (PAH) patients who have a PVR>1000 dynes.sec.cm-5 despite treatment ...	Trade Name: Glivec® Product Code: QTI571 INN or Proposed INN: IMATINIB MESYLATE	Novartis Pharma AG	NULL	Not Recruiting			Female: yes Male: yes	140		France;Belgium;Spain;Austria;Germany;Italy;United Kingdom
5	EUCTR2009-018167-26-GB (EUCTR)	07/09/2010	21/06/2010	An extension study to QTI571A2301 to evaluate the longterm safety, tolerability and efficacy of oral ...	An extension study to QTI571A2301 to evaluate the longterm safety, tolerability and efficacy of oral ...	Pulmonary arterial hypertension (PAH) patients who have a PVR=800 dynes.sec.cm-5 despite treatment w ...	Trade Name: Glivec® Product Code: QTI571 INN or Proposed INN: IMATINIB MESYLATE Trade Name: Glivec® Prod ...	Novartis Pharma AG	NULL	Not Recruiting			Female: yes Male: yes	140	Human pharmacology (Phase 1): no Therapeutic exploratory (Phase 2): no Therapeutic confirmatory - (P ...	France;Belgium;Spain;Austria;Germany;Italy;United Kingdom
6	EUCTR2009-018167-26-BE (EUCTR)	31/08/2010	18/05/2010	An extension study to QTI571A2301 to evaluate the longterm safety, tolerability and efficacy of oral ...	An extension study to QTI571A2301 to evaluate the longterm safety, tolerability and efficacy of oral ...	Pulmonary arterial hypertension (PAH) patients who have a PVR=800 dynes.sec.cm-5 despite treatment w ...	Trade Name: Glivec® Product Code: QTI571 INN or Proposed INN: IMATINIB MESYLATE	Novartis Pharma AG	NULL	Not Recruiting			Female: yes Male: yes	160	Phase 3	France;Spain;Belgium;Austria;Germany;Italy;United Kingdom
7	EUCTR2009-018167-26-DE (EUCTR)	04/05/2010	11/03/2010	An extension study to QTI571A2301 to evaluate the longterm safety, tolerability and efficacy of oral ...	An extension study to QTI571A2301 to evaluate the longterm safety, tolerability and efficacy of oral ...	Pulmonary arterial hypertension (PAH) patients who have a PVR=800 dynes.sec.cm-5 despite treatment w ...	Trade Name: Glivec® Product Code: QTI571 INN or Proposed INN: IMATINIB MESYLATE Trade Name: Glivec® Prod ...	Novartis Pharma AG	NULL	Not Recruiting			Female: yes Male: yes	140		France;Belgium;Spain;Austria;Germany;Italy;United Kingdom
8	EUCTR2009-018167-26-AT (EUCTR)	15/04/2010	16/02/2010	An extension study to QTI571A2301 to evaluate the longterm safety, tolerability and efficacy of oral ...	An extension study to QTI571A2301 to evaluate the longterm safety, tolerability and efficacy of oral ...	Pulmonary arterial hypertension (PAH) patients who have a PVR=800 dynes.sec.cm-5 despite treatment w ...	Trade Name: Glivec® Product Code: QTI571 INN or Proposed INN: IMATINIB MESYLATE	Novartis Pharma Services AG	NULL	Not Recruiting			Female: yes Male: yes	140		France;Belgium;Spain;Austria;Germany;Italy;United Kingdom
9	EUCTR2009-012057-38-NL (EUCTR)	05/01/2010	23/11/2009	A 24-week randomized placebo-controlled, double-blind multi-center clinical trial evaluating the eff ...	A 24-week randomized placebo-controlled, double-blind multi-center clinical trial evaluating the eff ...	Pulmonary arterial hypertension (PAH) patients who have a PVR>1000 dynes.sec.cm-5 despite treatment ...	Trade Name: Glivec® Product Code: QTI571 INN or Proposed INN: IMATINIB MESYLATE	Novartis Pharma AG	NULL	Not Recruiting			Female: yes Male: yes	200		United Kingdom;Germany;Netherlands;Belgium;France;Spain;Italy;Austria;Sweden
10	EUCTR2009-012057-38-FR (EUCTR)	21/09/2009	07/07/2009	A 24-week randomized placebo-controlled, double-blind multi-center clinical trial evaluating the eff ...	A 24-week randomized placebo-controlled, double-blind multi-center clinical trial evaluating the eff ...	Pulmonary arterial hypertension (PAH) patients who have a PVR>1000 dynes.sec.cm-5 despite treatment ...	Trade Name: Glivec® Product Code: QTI571 INN or Proposed INN: IMATINIB MESYLATE	Novartis Pharma AG	NULL	Not Recruiting			Female: yes Male: yes	200		France;Belgium;Spain;Austria;Netherlands;Germany;United Kingdom;Italy;Sweden

First Previous1 2Next Last

先頭へ